Schedule 13D ownership disclosure
REPLICEL LIFE SCIENCES INC.
Security class unavailable · CUSIP: 76027P400
Event date: 2021-12-17
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 3,986,687
- Percent of class
- 10.3400%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001085037-21-000107
- Form type
- SC 13D
- Filer
- MAINPOINTE PHARMACEUTICALS, LLC
- CIK
- CIK 1864509
- Filed
- Dec 21, 2021
- Reporting period
- Dec 17, 2021
- Description
- Schedule 13D beneficial ownership